Piper Jaffray reiterates an 'Overweight' rating and price target of $26 for Impax Laboratories (Nasdaq: IPXL), following tentative FDA approval ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE